Support Alert

Class 4 Medicines Defect Information: Inhixa solution for injection in pre-filled syringe (enoxaparin sodium)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issues a Class 4 medicines defect information drug alert for Inhixa solution for injection in pre-filled syringes. Techdow Europe AB has issued a Direct Healthcare Professional Communication (DHPC) due to rare cases of premature self-activation of the safety device in unused, unopened pre-filled Inhixa syringes. When premature activation has occurred, administration is not possible.

Further details of the alert, the affected products, and action to take are available on the MHRA website.

Loading...